Medicare AdvantageCoverageMedium impact
MA08.082o, Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and Related Biosimilars
Independence Blue Cross·Oncology, Hematology, Pharmacy·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
MA08.082o policy updates coverage and medical necessity criteria for four granulocyte-colony stimulating factor (G-CSF) medications: Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®), and related biosimilars, effective January 1, 2026. This is a recent pharmacy policy change that may affect prior authorization requirements, covered indications, or reimbursement terms for these injectable supportive care drugs used primarily in oncology and hematology.
Action Required
By December 31, 2025: Billing team must obtain and review the complete MA08.082o policy document from the provided URL to identify specific billing code changes, prior authorization requirements, and medical necessity criteria updates. Update billing system rules, EMR templates, and prior authorization submission protocols to reflect new coverage guidelines for Ryzneuta, Rolvedon, Neulasta, and biosimilars. Coordinate with providers in hematology and oncology departments to communicate any new documentation or authorization requirements. Beginning January 1, 2026, ensure all claims for these G-CSF products comply with updated policy terms or face potential denials.